| Time | Session |
|---|
|
2:15 p.m.
2:45 p.m.
|
Combination Effect of Finerenone and Empagliflozin in Participants With Chronic Kidney Disease and Type 2 Diabetes Using a UACR Endpoint Study (CONFIDENCE)—Baseline Characteristic
|
|
2:45 p.m.
3:15 p.m.
|
Clinical and Safety Outcomes of Semaglutide by CKD Severity in the FLOW trial
KatherineTuttle
Oral Abstract Presenter
University of Washington School of Medicine, Division of NephrologyUnited States
|
|
3:15 p.m.
3:45 p.m.
|
Results From the REGENCY Trial Assessing Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
|